

Super Quick Covid Treatment Update

Mike Hori, MD



Evusheld

Evusheld

- Two monoclonal antibodies (tixagevimab co-packaged with cilgavimab),
- Used to PREVENT COVID in patients unlikely to respond to vaccination (not for active infection like the other monoclonals)
- Given IM in the infusion center, 2 shots
- Serious side effects: allergic reactions including anaphylaxis and cardiac events in predisposed patients
- Remains an EUA medication
- Good for 6 months

Dosing

- Formerly 150 mg of each Mab, now 300 mg each, if <3 months from low dose injection, refer for 150 mg more of each

Current indications for Evusheld (not exhaustive), not likely to respond to vaccine

- Lung transplant recipient (any time frame).
- • Small bowel transplant recipient (any time frame).
- • Certain immunosuppressive medications within the past 12 months (including for solid organ transplant).
- • Anti-thymocyte globulin (ATG), SOT on other B or T cell depleting therapy
- • Anti-B-cell therapy (e.g., rituximab, alemtuzumab, others)
- • B-cell malignancies, on active treatment (e.g., B-cell lymphomas, chronic lymphocytic leukemia, acute B-cell lymphoblastic leukemia, etc.).
- • Multiple myeloma, on active treatment with two or more agent
- • Allogeneic stem cell transplant, within 12 months of transplant or continued graft vs host tx
- • Autologous stem cell transplant, within six months of transplant or continued graft vs host tx
- • Receipt of anti-CD19 or anti-BCMA (CAR)-T-cell immunotherapy, within six months of treatment.
- • Primary or secondary T-cell immunodeficiency, including severe combined immunodeficiency.
- • Recipient of more than one active transplant, different organs (any time frame), e.g. kidney-pancreas, heart-kidney
- • Hematologic malignancies under active treatment.
- HIV with CD4 < 50

Other requirements

INCLUSION CRITERIA

12y/o+ weighing $\geq 40\text{kg}$

AND

NOT currently infected* with COVID+ or have had recent exposure** to COVID+ patient

AND

Have moderate-severe immunocompromised state due to a medical condition (see Box 1)

AND

at least 14 days after COVID vaccination

Definitions:

*Not currently infected = negative test within 24 hours or no COVID symptoms for past 10 days.

**Recent exposure = within 8 days of Evusheld administration

Work flow

MD WORKFLOW

- Review patients for inclusion criteria and discuss benefits/risks.
- If patient consents, document in EPIC using **.EVUSHELDCONSENT**. Inform patient, current treatment with Evusheld is recommended every 6 months
- If discussed at office visit, add Fact Sheet to Patient Instructions in AVS using **.EVUSHELDAVS**
- **Order Evusheld in either a therapy plan (if available) or order via a paper order.** For paper order: please write for “Evusheld 600mg IM x 1”.

Therapy Plan

No assigned therapy plan

Search

Available (8)

- 812 AND FOLIC ACID
- ENOXAPARIN TEACHING
- EVUSHELD
- HYDRATION
- LAB DRAW FLUSHES

Close

Antibiotics

No assigned therapy plan

Search

Available (10)

Therapy Plan Properties - EVUSHELD

Plan name: EVUSHELD

Plan start date: [Red icon]

Lead provider: [Search icon]

Treatment department: VMC INFUSION [Search icon]

Problems Preview Plan

EVUSHELD

interaction checking is suppressed for medications within this plan.
No review required for this plan.

Orders

	Interval	Defier Until	Duration
Infusion Therapy Non Chemo			
<input checked="" type="checkbox"/> tosgavimab-cilgavimab (EVUSHELD) IM injection 300 mg	Once		1 treatment
Emergency Medications			
<input checked="" type="checkbox"/> Nursing Communication	PRN		Until discontinued

EPIC therapy plans

- Currently available in EPIC for ID, rheum and oncology
- As noted, paper orders for others
- If you would like to refer to ID to assist with an appropriate patient, we can and have done this for patients, typically with a quick visit.